Clinical Trial

Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 28, 2020 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.
Summary
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that concurrent and adjuvant PD-1 treatment added to concurrent chemo-radiotherapy could further decrease the rate of disease progression and improve the survival outcome of patients with unresectable locally recurrent nasopharyngeal carcinoma compared with those treated with concurrent chemo-radiotherapy alone.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-06-27; most recent amendment 2020-09-24.
Status change: Not Yet Recruiting → Recruiting 2020-07-01
Trial Details
NCT Number NCT04453813
Lead Sponsor Sun Yat-sen University
Collaborators: Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhongshan People's Hospital, Guangdong, China, Yuebei People's Hospital, Wuzhou Red Cross Hospital, Fifth Affiliated Hospital, Sun Yat-Sen University
Conditions Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy, PD-1 Treatment
Enrollment 226 participants
Start Date 2020-07-03
Primary Completion 2025-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2020-09-28